Navigation Links
By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates
Date:6/7/2012

GAITHERSBURG, MD, June 7 As one of the few probiotics with medical food designation for specific illnesses, VSL#3 has been the subject of a collection of more than 80 studies that have demonstrated its use in the dietary management of IBS, ulcerative colitis, and an ileal pouch. Ulcerative colitis patients, in particular, have been shown to benefit from adding VSL#3 medical food to their prescription drug regimen. One particular study shows that the combination of VSL#3 and traditional drug therapy can improve remission rates over drug therapy alone by 10 to 17 percent, and can initiate remission 47 to 69 percent faster. The 8-week study*, conducted in Rome, involved 90 patients who had newly diagnosed or recently relapsed mild-to-moderate UC and compared the effects of the combination of VSL#3 and balsalazine (Colazal), an anti-inflammatory drug commonly prescribed for the treatment of ulcerative colitis, to the use of balsalazine alone and mesalazine (Canasa) alone.

The trial results concluded that the use of low-dose balsalazide and VSL#3 was significantly superior (p<0.02) in obtaining remission than just the use of balsalazide alone (10 percent improvement) and mesalazine alone (17 percent improvement). The VSL#3/balsalazine combination also initiated remission faster than the drug therapy alone with an average of 4 days versus 7.5 days (balsalazide only) and 13 days (mesalazine only). The improvement of well-being and reduction in bowel frequency was significant as well1.

"Many UC patients try a variety of methods in order to extend their time between flare-ups and obtain remission," said Mary Berry, senior product manager at Sigma-Tau Pharmaceuticals, Inc., maker of VSL#3. "By having a personalized regimen with a drug, such as balsalazide, and adding VSL#3 for their dietary management, patients can see a positive and quick remission that will work for them."

Ulcerative colitis is a chronic disease that causes inflammation and sores, called ulcers, in the inner lining of the large intestine, which includes the colon and the rectum. The inflammation causes erosion of the lining of the colon, leading to bleeding, production of pus, diarrhea, and severe abdominal discomfort.

According to Berry, VSL#3 stands apart from other probiotics since it is not a supplement, but a refrigerated medical food that consists of 8 strains of live, freeze-dried lactic acid bacteria. "It is one of the few probiotic preparations supported by Level 1 (double-blind, placebo-controlled) scientific data, and is the only probiotic recognized as an effective tool in the dietary management of ileal pouch by the American College of Gastroenterology1 and by the Cochrane Review2," says Berry.


'/>"/>

Contact: Nicole Egan
negan@rlapr.com
914-241-0086 x28
Robin Leedy & Associates, Inc.
Source:Eurekalert

Related biology news :

1. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
2. Pain relief with PAP injections may last 100 times longer than a traditional acupuncture treatment
3. Some improved cookstoves may emit more pollution than traditional mud cookstoves
4. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
5. Neural stem cell transplants for spinal cord injury maximized by combined, complimentary therapies
6. New discoveries about brain-hand connection sought to improve therapies, treatments, prosthetics
7. Cardio fitness levels of breast cancer patients may affect survival
8. Modest alcohol intake associated with less inflammation in patients with common liver disease
9. Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes
10. New data suggests interferon-free therapy around the corner for HCV patients
11. Drug interactions wont exclude HCV transplant or HIV co-infected patients from treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
(Date:1/18/2017)... , Jan. 18, 2017 ... company that supports the entire spectrum of clinical ... been another record-breaking year for the organization in ... interest in MedNet,s eClinical products and services. The ... tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... -- New research undertaken by Fit Small Business has ... were simply asked which office technology had they not used ... issue.  Insights on what will be key features ... and industry leaders including Penelope Trunk , Martin ... Some of these findings included; ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... -- Bioptix, Inc. (Nasdaq: BIOP ... 14, 2017 the Board of Directors of the Company ... certain employees associated with the September 2016 acquisition of ... on January 16, 2017 and terminations are expected to ... severance benefits in certain circumstances of up to one ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... how current market conditions have influenced the most recent ... Regulus Therapeutics Inc. (NASDAQ: RGLS ), Abeona ... Inc. (NASDAQ: TBPH ), and Sage Therapeutics ... new research report by Grand View Research, global Biotech market size ...
(Date:1/19/2017)... -- Research and Markets has announced the addition of ... Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" report ... ... projected to reach $15,737 million by 2022 from $6,521 in 2015, ... Omic technologies segment accounted for more than half of ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the ... 2025" report to their offering. Report ... provides a detailed analysis on current and future market trends to identify ... market values as the base numbers Key market trends ...
Breaking Biology Technology: